Government ❯ Health Policy ❯ Drug Regulation

FDA

Mifepristone Public Health Cerebral Folate Deficiency Leucovorin Leucovorin Approval Public Health Initiatives Biologic Drugs Acetaminophen National Interests Appointments Policy Changes Drug Recalls Psychedelic Research

FDA Names First 9 Drugs for ‘National Priority’ Fast-Track Reviews, Targeting 1–2-Month Decisions

The pilot prioritizes therapies tied to public health, affordability or U.S. manufacturing; a second round is expected within weeks.

FDA Launches Mifepristone Safety Review, Weighing How the Drug Is Dispensed